Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
This new study offers greater relief to India's psoriasis patients, hopefully
Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...
CNBCTV183d
Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment
The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...
Medical Dialogues2d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Stocks to Watch Today: Lupin, Tata Power, Nazara Tech, Shilpa Medicare, GMR Airports, IRB Infra, Railtel, Shyam Metalics in focus on 10 March
Stocks like India Pesticides, HFCL, NDR Auto Components, JSW Steel, GR Infraprojects, Biocon, Oil and Natural Gas Corporation ...
Morningstar3d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
This Phase 3 study reaffirms the quality and therapeutic equivalence of YESINTEK compared to reference product, Stelara. The study demonstrated equivalent efficacy, safety, immunogenicity ...
NDTV Profit15h
Stock Market Today: All You Need To Know Going Into Trade On March 10
Nifty March Futures up by 0.08% at a premium of 97.45 points. Nifty Options March 13 Expiry: Maximum call open interest at 20 ...
Le Lézard3d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintektm Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Managed Healthcare Executive6d
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available
The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.